

Ab Initio Whole Cell Kinetic Model of *Streptococcus salivarius* JIM8777 (stjDNV26)

Diya Nanthakumarvani^{1,2}, Leesha Haarshiny Perumal^{1,2}, Atoshi Abirami RajKumar^{1,2}, Cheryl Kai Ning Kang^{1,2}, Sragvi Verma^{1,2}, Shafeeqa Abul-Hasan^{1,2} and Maurice HT Ling^{2,3,4*}

¹Department of Applied Sciences, Northumbria University, United Kingdom.

²Management Development Institute of Singapore, Singapore.

³Newcastle Australia Institute of Higher Education, University of Newcastle, Australia.

⁴HOHY PTE LTD, Singapore.

Citation: Diya Nanthakumarvani, Leesha Haarshiny Perumal, Atoshi Abirami RajKumar, et al. *Ab Initio Whole Cell Kinetic Model of Streptococcus salivarius JIM8777 (stjDNV26)*. American J Pathol Res. 2026; 5(1): 1-4.

*Correspondence:

Maurice HT Ling, Newcastle Australia Institute of Higher Education, University of Newcastle, Australia.

Received: 26 Dec 2025; **Accepted:** 05 Jan 2026; **Published:** 08 Jan 2026

ABSTRACT

Streptococcus salivarius is one of the earliest bacterial colonies of the human host which is established itself in the oral cavity within the first day after birth. It has been considered for probiotic applications due to its low virulence factor, including its potential benefits in children's health. Mathematical kinetic models generate time-dependent profiles of simulated metabolites, which can be used to guide metabolic engineering approaches. However, there is no kinetic model of *S. salivarius* to-date. In this study, we present a whole cell simulatable kinetic model of *S. salivarius* JIM8777, stjDNV26, constructed using enzymatic reactions identified via enzymes from its published genome. The resulting model consists of 842 metabolites, 364 enzymes with corresponding transcriptions and translations, and 778 enzymatic reactions; which can be a baseline model for incorporating other cellular and growth processes, or as a system to examine cellular resource allocations necessary for engineering.

Keywords

Whole-cell model, Kinetic model, Differential equations, Oral commensal, Probiotic, Human Infant, AdvanceSyn Toolkit.

Introduction

Streptococcus salivarius is one of the earliest bacterial colonizers of the human host, establishing itself in the oral cavity within the first days after birth and persisting as a dominant and stable component of the oral and upper respiratory tract microbiota throughout life [1]. *S. salivarius* exhibits immunomodulatory properties [2,3], and is generally regarded as a commensal organism with low virulence [4]. Hence, it has been considered for probiotic applications [5-7], including its potential benefits in children's health and prophylaxis [8]. As a result, various strains of engineered *S. salivarius* have been evaluated for tolerance and probiotic potential [9-11].

Mathematical modelling is a useful tool in metabolic engineering. Two broad modelling traditions dominate this space [12,13]: GSMS

and KMs. GSMS, being constraint-based, are powerful but limited largely to predicting reaction rates. KMs, however, can forecast both fluxes and product yields [14], giving them an added layer of utility. They also handle *in silico* gene knock-ins with greater flexibility than GSMS [15]. These strengths collectively make KMs an appealing choice for early-stage assessment of engineering alternatives. In recent years, this has led to an increasing call across the field to create more robust and readily accessible kinetic models [16,17].

However, there is no whole cell kinetic models of *S. salivarius* to date. Hence, this study aims to construct a KM of *S. salivarius* JIM8777, originally was isolated from the oral cavity of a healthy human infant, using *ab initio* approach by identifying enzymes from its published genome [18], and identifying the corresponding reaction from KEGG [19]. The result is a whole cell KM of *S. salivarius* JIM8777, named as stjDNV26, using the nomenclature proposed by Cho and Ling [20], which consists of 842 metabolites,

364 enzymes with corresponding transcriptions and translations, and 778 enzymatic reactions.

Materials and Methods

Identification of Reactome

The annotated genome of *Streptococcus salivarius* JIM8777 [18] (NCBI RefSeq assembly GCF_000253315.1; NCBI GenBank Accession NC_017595.1) was used as source to identify enzymatic genes using the process previously described [15,21,22]. Briefly, each enzymatic gene was identified as a presence of complete Enzyme Commission (EC) number in the GenBank record and mapped into reaction IDs via KEGG Ligand Database for Enzyme Nomenclature [19]. For example, EC 1.1.1.23 (<https://www.genome.jp/entry/1.1.1.23>) catalyses reactions R01158, R01163, and R03012; where the substrates and products of each reaction can be identified.

Model Development

The model was developed using the principles described in Sim et al. [23]. Using BioNumbers as a foundation, transcription in *Escherichia coli* can be quantified with reasonable confidence. Approximately 3000 RNA polymerases exist per cell (BioNumbers 106199) [24], though only one-quarter participate in active elongation (BioNumbers 111676) [25]. Their polymerization speed (22 nucleotides per second) (BioNumbers 104109) [26] and the average nucleotide mass (339.5 Da) correspond to an output of about 5600 kDa/s ($\approx 9.3 \times 10^{-18}$ g/s). When normalized to a cellular volume of 7×10^{-16} L [27] and 4225 coding genes (BioNumbers 105443) [28], this results in about 2.92 micromolar per gene per second. With mean mRNA stability of 107.56 seconds (BioNumbers 107666) [29] (0.93% decay/s) (BioNumbers 109924) [30], we obtain: $d[mRNA]/dt = 0.00292 - 0.0093[mRNA]$. Protein production proceeds at 0.278 peptides/s per transcript (BioNumbers 106382) [31], while *E. coli* proteins degrade at about 2.78e-6 per second. Hence: $d[peptide]/dt = 0.278[mRNA] - 0.00000278[peptide]$. The overall model was implemented as ODEs [21,32] using representative kinetic constants ($k_{cat} = 13.7/s$, $K_m = 1\text{ mM}$) [33], structured per AdvanceSyn specifications [34].

Model Simulation

The constructed model was tested for simulability using AdvanceSyn Toolkit [34]. Initial concentrations of all mRNA and enzymes were set to 0 mM. Initial concentrations of all metabolites were set to 1 mM except the following which were set to 1000 mM: (I) C00001 (Water), (II) C00002 (ATP), (III) C00003 (NAD+), (IV) C00004 (NADH), (V) C00005 (NADPH), (VI) C00006 (NADP+), (VII) C00007 (Oxygen), (VIII) C00008 (ADP), (IX) C00009 (Orthophosphate), (X) C00010 (CoA), (XI) C00011 (Carbon Dioxide), (XII) C00013 (Diphosphate), (XIII) C00014 (Ammonia), (XIV) C00015 (UDP), (XV) C00016 (FAD), (XVI) C00019 (S-Adenosyl-L-methionine), (XVII) C00020 (AMP), (XVIII) C00021 (S-Adenosyl-L-homocysteine), (XIX) C00022 (Pyruvate), (XX) C00024 (Acetyl-CoA), (XXI) C00025 (L-Glutamate), (XXII) C00029 (UDP-glucose), (XXIII) C00031 (D-Glucose), (XXIV) C00035 (GDP), (XXV) C00037

(Glycine), (XXVI) C00041 (L-Alanine), (XXVII) C00047 (L-Lysine), (XXVIII) C00049 (L-Aspartate), (XXIX) C00062 (L-Arginine), (XXX) C00064 (L-Glutamine), (XXXI) C00065 (L-Serine), (XXXII) C00078 (L-Tryptophan), (XXXIII) C00079 (L-Phenylalanine), (XXXIV) C00080 (H⁺), (XXXV) C00082 (L-Tyrosine), (XXXVI) C00097 (L-Cysteine), (XXXVII) C00147 (Adenine), (XXXVIII) C00148 (L-Proline), (XXXIX) C00183 (L-Valine). The model was simulated using the fourth-order Runge-Kutta method [35,36] from time zero to 3600 seconds with timestep of 0.1 second, and the concentrations of metabolites were bounded between 0 millimolar and 1000 millimolar. The simulation results were sampled every 2 seconds.

Results and Discussion

The annotated genome of *Streptococcus salivarius* JIM8777 [18] consists of 2055 genes, including 1936 protein coding sequences. 364 unique EC numbers consisting of 778 enzymatic reactions involving 842 metabolites were identified and developed into a model based on AdvanceSyn Model Specification [34]. In addition, 728 ODEs acting as placeholder for enzyme transcriptions and translations were added.

The stjDNV26 model was run using the AdvanceSyn Toolkit [34], and the resulting simulation curves in Figure 1 confirm that the model is free from syntax errors and structurally consistent as previously argued [15,22,37-41]. Achieving such a clean run is an important indicator of correctness given the complexity of whole-cell kinetic systems. The apparent increased rate of acetate production over glyoxylate may arise due to the universal use of median kinetic parameters [42], which ignore enzyme-specific behaviour and should not be interpreted biologically. The key contribution here is a simulatable and extensible whole-cell kinetic model for *S. salivarius* JIM8777. It can serve as a platform for integrating more biological realism, additional processes such as growth coupling, or comparative studies of resource allocation patterns under various metabolic scenarios [43-45].




Figure 1: Selection of Simulation Results.

Conclusion

We present an *ab initio* whole cell kinetic model of *Streptococcus salivarius* JIM8777, stjDNV26; comprising of 842 metabolites,

364 enzymes with corresponding transcriptions and translations, and 778 enzymatic reactions.

Supplementary Materials

Reaction descriptions and model can be download from <https://bit.ly/stjDNV26>.

References

1. Kaci G, Goudercourt D, Dennin V, et al. Anti-Inflammatory Properties of *Streptococcus salivarius*, A Commensal Bacterium of the Oral Cavity and Digestive Tract. *Appl Environ Microbiol*. 2014; 80: 928-934.
2. Van Den Bogert B, Meijerink M, Zoetendal EG, et al. Immunomodulatory Properties of *Streptococcus* and *Veillonella* Isolates from the Human Small Intestine Microbiota. *PLoS One*. 2014; 9: e114277.
3. Zhu P, Shao R, Xu P, et al. *Streptococcus salivarius* Ameliorates the Destructive Effect on the Epithelial Barrier by Inhibiting the Growth of *Prevotella melaninogenica* via Metabolic Acid Production. *Mol Oral Microbiol*. 2024; 39: 407-416.
4. Delorme C, Abraham AL, Renault P, et al. Genomics of *Streptococcus salivarius*, A Major Human Commensal. *Infect Genet Evol*. 2015; 33: 381-392.
5. Bidossi A, De Grandi R, Toscano M, et al. Probiotics *Streptococcus salivarius* 24SMB and *Streptococcus oralis* 89a Interfere with Biofilm Formation of Pathogens of the Upper Respiratory Tract. *BMC Infect Dis*. 2018; 18: 653.
6. Sriham K, Daengprok W, Niamsup P, et al. Characterization of *Streptococcus salivarius* as New Probiotics Derived From Human Breast Milk and Their Potential on Proliferative Inhibition of Liver and Breast Cancer Cells and Antioxidant Activity. *Front Microbiol*. 2021; 12: 797445.
7. Choudhary P, Kraatz H-B, Lévesque CM, et al. Microencapsulation of Probiotic *Streptococcus salivarius* LAB813. *ACS Omega*. 2023; 8: 12011-12018.
8. Al-Akel FC, Chipperi LE, Eszter VK, et al. *Streptococcus salivarius* Role as a Probiotic in Children's Health and Disease Prophylaxis - A Systematic Review. *Life*. 2024; 14: 1613.
9. Di Pierro F, Bugti AA, Bano A, et al. Study to Evaluate the Safety and Tolerability of *Streptococcus salivarius* eK12, A Genetically Modified Strain Derived from the Oral Probiotic *S. salivarius* K12: Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial. *Front Nutr*. 2025; 12: 1701611.
10. Do H, Li ZR, Tripathi PK, et al. Engineered Probiotic Overcomes Pathogen Defences Using Signal Interference and Antibiotic Production to Treat Infection in Mice. *Nat Microbiol*. 2024; 9: 502-513.
11. Burton JP, Wescombe PA, Macklaim JM, et al. Persistence of the Oral Probiotic *Streptococcus salivarius* M18 Is Dose Dependent and Megaplasmid Transfer Can Augment Their Bacteriocin Production and Adhesion Characteristics. *PLoS One*. 2013; 8: e65991.
12. Richelle A, David B, Demaegd D, et al. Towards a Widespread Adoption of Metabolic Modeling Tools in Biopharmaceutical Industry: A Process Systems Biology Engineering Perspective. *NPJ Syst Biol Appl*. 2020; 6: 6.
13. Lee YQ, Choi YM, Park SY, et al. Genome-scale metabolic model-guided systematic framework for designing customized live biotherapeutic products. *NPJ Syst Biol Appl*. 2025; 11: 73.
14. Prabhu S, Kosir N, Kothare MV, et al. Derivative-Free Domain-Informed Data-Driven Discovery of Sparse Kinetic Models. *Ind Eng Chem Res*. 2025; 64: 2601-2615.
15. Yeo KY, Arivazhagan M, Senthilkumar A, et al. Ab Initio Whole Cell Kinetic Model of *Yarrowia lipolytica* CLIB122 (yliYKY24). *Medicon Medical Sciences*. 2025; 8: 01-06.
16. Foster CJ, Wang L, Dinh HV, et al. Building Kinetic Models for Metabolic Engineering. *Curr Opin Biotechnol*. 2021; 67: 35-41.
17. Lázaro J, Wongprommoon A, Júlvez J, et al. Enhancing genome-scale metabolic models with kinetic data: resolving growth and citramalate production trade-offs in *Escherichia coli*. *Bioinform Adv*. 2025; 5: vba166.
18. Guédon E, Delorme C, Pons N, et al. Complete Genome Sequence of the Commensal *Streptococcus salivarius* Strain JIM8777. *J Bacteriol*. 2011; 193: 5024-5025.
19. Okuda S, Yamada T, Hamajima M, et al. KEGG Atlas mapping for global analysis of metabolic pathways. *Nucleic Acids Res*. 2008; 36: W423-W426.
20. Cho JL, Ling MH. Adaptation of Whole Cell Kinetic Model Template, UniKin1, to *Escherichia coli* Whole Cell Kinetic Model, ecoJC20. *EC Microbiology*. 2021; 17: 254-260.
21. Kwan ZJ, Teo W, Lum AK, et al. Ab Initio Whole Cell Kinetic Model of *Stutzerimonas balearica* DSM 6083 (pbmKZJ23). *Acta Scientific Microbiology*. 2024; 7: 28-31.
22. Maiyappan S, Sim SS, Ramesh G, et al. Four Ab Initio Whole Cell Kinetic Models of *Bacillus subtilis* 168 (bsuLL25) 6051-HGW (bshSM25), N33 (bsuN33SS25), FUA2231 (bsuGR25). *J Clin Immunol Microbiol*. 2025; 6: 1-6.
23. Sim BJH, Tan NTF, Ling MHT. Multilevel Metabolic Modelling Using Ordinary Differential Equations. *Encyclopedia of Bioinformatics and Computational Biology*. 2025; 4: 491-498.
24. Müller-Hill B. The lac Operon: A Short History of a Genetic Paradigm (Berlin, Germany). 1996.
25. Churchward G, Bremer H, Young R. Transcription in Bacteria at Different DNA Concentrations. *J Bacteriol*. 1982; 150: 572-581.
26. Gray WJ, Midgley JE. The Control of Ribonucleic Acid Synthesis in Bacteria. The Synthesis and Stability of Ribonucleic Acid in Rifampicin-Inhibited Cultures of *Escherichia coli*. *Biochem J*. 1971; 122: 161-169.
27. Kubitschek HE. Cell Volume Increase in *Escherichia coli* After Shifts to Richer Media. *J Bacteriol*. 1990; 172: 94-101.

28. Hu P, Janga SC, Babu M, et al. Global Functional Atlas of Escherichia coli Encompassing Previously Uncharacterized Proteins. *PLoS Biol.* 2009; 7: e96.
29. So LH, Ghosh A, Zong C, et al. General Properties of Transcriptional Time Series in Escherichia coli. *Nat Genet.* 2011; 43: 554-560.
30. Maurizi MR. Proteases and Protein Degradation in Escherichia coli. *Experientia.* 1992; 48: 178-201.
31. Schwahnässer B, Busse D, Li N, et al. Corrigendum: Global Quantification of Mammalian Gene Expression Control. *Nature.* 2013; 495: 126-127.
32. Murthy MV, Balan D, Kamarudin NJ, et al. UniKin1: A Universal, Non-Species-Specific Whole Cell Kinetic Model. *Acta Scientific Microbiology.* 2020; 3: 04-08.
33. Bar-Even A, Noor E, Savir Y, et al. The Moderately Efficient Enzyme: Evolutionary and Physicochemical Trends Shaping Enzyme Parameters. *Biochemistry.* 2011; 50: 4402-4410.
34. Ling MH. AdvanceSyn Toolkit: An Open Source Suite for Model Development and Analysis in Biological Engineering. *MOJ Proteomics Bioinform.* 2020; 9: 83-86.
35. Yong B. The Comparison of Fourth Order Runge-Kutta and Homotopy Analysis Method for Solving Three Basic Epidemic Models. *Journal of Physics Conf Series.* 2019; 1317: 012020.
36. Ling MH. COPADS IV: Fixed Time-Step ODE Solvers for a System of Equations Implemented as a Set of Python Functions. *ACSIJ.* 2016; 5: 5-11.
37. Saisudhanbabu T, Yeo KY, Arivazhagan M, et al. Ab Initio Whole Cell Kinetic Model of Limosilactobacillus fermentum EFEL6800 (lfeTS24). *EC Clinical and Medical Case Reports.* 2025; 8: 01-04.
38. Arivazhagan M, Senthilkumar A, Yeo KY, et al. Ab Initio Whole Cell Kinetic Model of Bifidobacterium bifidum BGN4 (bbfMA24). *Acta Scientific Nutritional Health.* 2025; 9: 42-45.
39. Senthilkumar A, Madhunisha A, Yeo KY, et al. Ab Initio Whole Cell Kinetic Model of Lactobacillus acidophilus NCFM (lacAS24). *J Clin Immunol Microbiol.* 2025; 6: 1-5.
40. Wong TB, Le MA, Arivazhagan M, et al. Ab Initio Whole Cell Kinetic Models of Escherichia coli BL21 (ebeTBSW25) and MG1655 (ecoMAL25). *Scholastic Medical Sciences.* 2025; 3: 01-04.
41. Ambel WB, Tan LP, Toh D, et al. UniKin2 – A Universal, Pan-Reactome Kinetic Model. *IJRMCS.* 2025; 3: 77-80.
42. Bar-Even A, Milo R, Noor E, et al. The Moderately Efficient Enzyme: Futile Encounters and Enzyme Floppiness. *Biochemistry.* 2015; 54: 4969-4977.
43. Ahn-Horst TA, Mille LS, Sun G, et al. An Expanded Whole-Cell Model of *E. coli* Links Cellular Physiology with Mechanisms of Growth Rate Control. *NPJ Syst Biol Appl.* 2022; 8: 30.
44. Chagas M da S, Trindade Dos Santos M, Argollo de Menezes M, et al. Boolean Model of the Gene Regulatory Network of *Pseudomonas aeruginosa* CCBH4851. *Front Microbiol.* 2023; 14: 1274740.
45. Hao T, Song Z, Zhang M, et al. Reconstruction of Metabolic-Protein Interaction Integrated Network of *Eriocheir sinensis* and Analysis of Ecdysone Synthesis. *Genes.* 2024; 15: 410.